Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock. MRNS has been the topic of several other research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of […]
StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock. MRNS has been the topic of several other research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of […]
